Endovascular Repair in Acute Complicated Type B Aortic Dissection: 3-Year Results from the Valiant US Investigational Device Exemption Study

• Main Author: Chang Young Lim
• Format: Article
• Language: English
• Published: Korean Society for Thoracic and Cardiovascular Surgery 2017-06-01
• Series: Korean Journal of Thoracic and Cardiovascular Surgery
• Subjects: Self expandable metallic stents; Aortic aneurysm; thoracic; Aortic dissection; Valiant captivia
• Online Access: http://www.kjtcvs.org/journal/download_pdf.php?doi=10.5090/kjtcs.2017.50.3.137
• ISSN: 2233-601X; 2093-6516

Acute complicated type B aortic dissection (TBAD) is a potentially catastrophic, life-threatening condition. If left untreated, there is a high risk of aortic rupture, irreversible organ or limb damage, or death. Several risk factors have been associated with acute complicated TBAD, including age and refractory hypertension. In the acute phase, even uncomplicated patients are more prone to develop complications if hypertension and pain are left medically untreated. Innovations in stent graft technologies have incrementally improved outcomes since their first use for this condition in 1999, though improvement is needed in mitigating periprocedural complications, adverse events, and mortality. In the past decade, endovascular repair has become the preferred treatment because of its superior outcomes to open repair and medical therapy. The Valiant Captivia Thoracic Stent Graft System is a third-generation endovascular stent graft with advancements in minimally invasive delivery, conformability to the anatomy, and the minimization of adverse sequelae. Herein, this stent graft is briefly reviewed and its 3-year outcomes are presented. Freedom from all-cause and dissection- related mortality was 79.1% a nd 9 0.0%, respectiv ely. T he V aliant C aptiv ia S tent G raft r epresents a safe, effective intervention for acute complicated TBAD. Continued surveillance is needed to verify its longer- term durability.